lanreotide + trastuzumab deruxtecan

Lanreotide + trastuzumab deruxtecan is an investigational combination therapy consisting of two distinct agents with complementary mechanisms of action, being explored primarily in oncology clinical trials. Lanreotide is a synthetic somatostatin analog used to inhibit hormone secretion and tumor growth in neuroendocrine tumors, while trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate (ADC) that targets HER2-expressing cancer cells and delivers a cytotoxic topoisomerase I inhibitor payload (deruxtecan) directly to the tumor. The rationale for combining these drugs lies in targeting both neuroendocrine features and HER2-driven oncogenic pathways, potentially offering synergistic antitumor effects for patients with advanced or metastatic cancers exhibiting both characteristics[1][4][5][6][9].